Testosterone depot injection in male hypogonadism: a critical appraisal

Aksam A Yassin1, Mohamed Haffejee21Clinic of Urology/Andrology, Segeberger Kliniken, Norderstedt-Hamburg, Germany and Department of Urology, Gulf Medical College School of Medicine, Ajman-UAE 2Urology Division at the University of Witwaterstrand & Johannesburg Hospital, Johannesburg, South A...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aksam A Yassin, Mohamed Haffejee
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/ecb7614f6e914006b7bf756c58570958
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ecb7614f6e914006b7bf756c58570958
record_format	dspace
spelling	oai:doaj.org-article:ecb7614f6e914006b7bf756c585709582021-12-02T01:34:48ZTestosterone depot injection in male hypogonadism: a critical appraisal1178-1998https://doaj.org/article/ecb7614f6e914006b7bf756c585709582008-01-01T00:00:00Zhttps://www.dovepress.com/testosterone-depot-injection-in-male-hypogonadism-a-critical-appraisal-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Aksam A Yassin1, Mohamed Haffejee21Clinic of Urology/Andrology, Segeberger Kliniken, Norderstedt-Hamburg, Germany and Department of Urology, Gulf Medical College School of Medicine, Ajman-UAE 2Urology Division at the University of Witwaterstrand & Johannesburg Hospital, Johannesburg, South AfricaAbstract: Testosterone compounds have been available for almost 70 years, but the pharmaceutical formulations have been less than ideal. Traditionally, injectable testosterone esters have been used for treatment, but they generate supranormal testosterone levels shortly after the 2- to 3-weekly injection interval and then testosterone levels decline very rapidly, becoming subnormal in the days before the next injection. The rapid fluctuations in plasma testosterone are subjectively experienced as disagreeable. Testosterone undecanoate is a new injectable testosterone preparation with a considerably better pharmacokinetic profile. After 2 initial injections with a 6-week interval, the following intervals between two injections are almost always 12-weeks, amounting eventually to a total of 4 injections per year. Plasma testosterone levels with this preparation are nearly always in the range of normal men, so are its metabolic products estradiol and dihydrotestosterone. The “roller coaster” effects of traditional parenteral testosterone injections are not apparent. It reverses the effects of hypogonadism on bone and muscle and metabolic parameters and on sexual functions. Its safety profile is excellent due to the continuous normalcy of plasma testosterone levels. No polycythemia has been observed, and no adverse effects on lipid profiles. Prostate safety parameters are well within reference limits. There was no impairment of uroflow. Testosterone undecanoate is a valuable contribution to the treatment options of androgen deficiency.Keywords: testosterone treatment, testosterone undecanoate, pharmacokinetic profile, clinical efficacy, side effects, sexual dysfunctionAksam A YassinMohamed HaffejeeDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 577-590 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Aksam A Yassin Mohamed Haffejee Testosterone depot injection in male hypogonadism: a critical appraisal
description	Aksam A Yassin1, Mohamed Haffejee21Clinic of Urology/Andrology, Segeberger Kliniken, Norderstedt-Hamburg, Germany and Department of Urology, Gulf Medical College School of Medicine, Ajman-UAE 2Urology Division at the University of Witwaterstrand & Johannesburg Hospital, Johannesburg, South AfricaAbstract: Testosterone compounds have been available for almost 70 years, but the pharmaceutical formulations have been less than ideal. Traditionally, injectable testosterone esters have been used for treatment, but they generate supranormal testosterone levels shortly after the 2- to 3-weekly injection interval and then testosterone levels decline very rapidly, becoming subnormal in the days before the next injection. The rapid fluctuations in plasma testosterone are subjectively experienced as disagreeable. Testosterone undecanoate is a new injectable testosterone preparation with a considerably better pharmacokinetic profile. After 2 initial injections with a 6-week interval, the following intervals between two injections are almost always 12-weeks, amounting eventually to a total of 4 injections per year. Plasma testosterone levels with this preparation are nearly always in the range of normal men, so are its metabolic products estradiol and dihydrotestosterone. The “roller coaster” effects of traditional parenteral testosterone injections are not apparent. It reverses the effects of hypogonadism on bone and muscle and metabolic parameters and on sexual functions. Its safety profile is excellent due to the continuous normalcy of plasma testosterone levels. No polycythemia has been observed, and no adverse effects on lipid profiles. Prostate safety parameters are well within reference limits. There was no impairment of uroflow. Testosterone undecanoate is a valuable contribution to the treatment options of androgen deficiency.Keywords: testosterone treatment, testosterone undecanoate, pharmacokinetic profile, clinical efficacy, side effects, sexual dysfunction
format	article
author	Aksam A Yassin Mohamed Haffejee
author_facet	Aksam A Yassin Mohamed Haffejee
author_sort	Aksam A Yassin
title	Testosterone depot injection in male hypogonadism: a critical appraisal
title_short	Testosterone depot injection in male hypogonadism: a critical appraisal
title_full	Testosterone depot injection in male hypogonadism: a critical appraisal
title_fullStr	Testosterone depot injection in male hypogonadism: a critical appraisal
title_full_unstemmed	Testosterone depot injection in male hypogonadism: a critical appraisal
title_sort	testosterone depot injection in male hypogonadism: a critical appraisal
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/ecb7614f6e914006b7bf756c58570958
work_keys_str_mv	AT aksamayassin testosteronedepotinjectioninmalehypogonadismacriticalappraisal AT mohamedhaffejee testosteronedepotinjectioninmalehypogonadismacriticalappraisal
_version_	1718402989733969920

Testosterone depot injection in male hypogonadism: a critical appraisal

Ejemplares similares